State-level density reporting laws are associated with increased breast density awareness and increased likelihood of conversations between women and providers regarding supplemental screening.
Women with Dense Breast Tissue have a higher-than-average risk of Breast Cancer.
Breast Density is one of the strongest, if not the strongest, predictor of the failure of mammography screening to detect cancer.
We're finding small, mammographically occult cancers (Invisible on Mammogram) at a significant rate and we're able to do so and still be efficient.
Withholding medical information from patients without their knowledge or consent is ethically unacceptable.
Mammographic breast density is a well-established and strong predictor of breast cancer risk.
It may be the greatest risk factor you never heard of.
Breast density exceeds other risk factors, including obesity, family history, and later in life childbirth.
Celebrating the Life, Work & Legacy of Dr. Nancy Cappello
JACR Study (Cappello, Richetelli & Lee) Women in States with Density Reporting Laws are more aware of breast density impact, prompting conversations betwen patient and provider
On March 28, 2019, the Department of Health and Human Services, the FDA announced changes to the MQSA (Mammography Quality Standards Act) to include reporting of dense breast tissue to the patient...
In “read" from the FDA “Breast Density”
"The Committee recognizes the importance of patients receiving their own personal medical information and directs the FDA to ensure that Mammography reports and summaries received by patients and their providers include appropriate information about breast density specified by the Secretary, including, at a minimum, the effect of breast density in masking the presence of breast cancer on a mammogram, the qualitative assessment of the provider who interpreted the mammogram, and a reminder to patients that individuals with dense breast tissue should talk with their providers if they have any questions or concerns about their summary”.